14 completed, 1 unknown. 8 Phase 2, 5 Phase 3, 2 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 3 | 5 | Completed 4, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
Follow MenACWY: new trials by email Literature Review of MenACWY trials Research Report on MenACWY
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. Shigella4V2, MenACWY - Shigellosis | Phase 2 | Completed | LimmaTech Biologics AG | 110 | 2025-04-07 | 2026-08-07 |
| A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants iNTS-GMMA Dose C, iNTS-GMMA Dose B, iNTS-GMMA Dose A - Salmonella Infections | Phase 2 | Completed | GlaxoSmithKline | 180 | 2024-01-15 | 2026-09-21 |
| Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 3657 | 2020-08-14 | 2024-03-05 |
| A Study of a Candidate COVID-19 Vaccine (COV003) ChAdOx1 nCoV-19 single dose + paracetamol, MenACWY single dose + paracetamol, ChAdOx1 nCoV-19 two dose + paracetamol - Coronavirus | Phase 3 | Unknown | University of Oxford | 10300 | 2020-06-02 | 2020-11-27 |
| A Study of a Candidate COVID-19 Vaccine (COV001) ChAdOx1 nCoV-19, MenACWY, ChAdOx1 nCoV-19 full boost - Coronavirus | Phase 1 / Phase 2 | Completed | University of Oxford | 1077 | 2020-04-23 | 2025-09-03 |
| A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Shigella 4V, MenACWY, Rabies - Shigellosis | Phase 1 / Phase 2 | Completed | LimmaTech Biologics AG | 597 | 2019-09-02 | 2026-06-23 |
| A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants Ad26.ZEBOV, MVA-BN-Filo, MenACWY - Ebola Virus Disease | Phase 2 | Completed | Janssen Vaccines & Prevention B.V. | 108 | 2019-08-19 | 2025-05-25 |
| A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age MenACWY liquid, MenACWY - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 1707 | 2018-08-30 | 2021-02-17 |
| Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years MenABCWY vaccine, rMenB+OMV NZ (Bexsero) vaccine, MenACWY (Menveo) vaccine - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 520 | 2018-07-09 | 2020-02-12 |
| A Sourcing Study to Collect Human Blood Samples From Healthy Adults rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) - Meningitis, Meningococcal | Phase 4 | Completed | GlaxoSmithKline | 1021 | 2018-03-08 | 2023-07-17 |
| Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo Ad26.ZEBOV, MVA-BN-Filo, MenACWY - Ebola Virus Disease | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 1023 | 2015-09-30 | 2022-07-18 |
| Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations MenACWY - Infections, Meningococcal | Phase 4 | Completed | GlaxoSmithKline | 128 | 2015-07-13 | 2019-06-27 |
| Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants Meningococcal group B Vaccine, rMenB+OMV NZ, Meningococcal ACWY Conjugate Vaccine, MenACWY - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 750 | 2014-06-05 | 2018-08-22 |
| Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents MenABCWY, Placebo, MenACWY - Meningococcal Disease | Phase 2 | Completed | Novartis Vaccines | 305 | 2014-05-01 | 2018-09-12 |
| Understanding the Immune Response to Meningitis Vaccines Meningococcal (Groups A, C, Y and W-135) Conjugate, Meningococcal polysaccharide A, C, Y and W135 and Menveo - Meningitis, Septicemia | Phase 3 | Completed | University of Oxford | 150 | 2009-06-01 | 2014-12-05 |
Meningococcal Infections (6) · Meningitis (5) · Meningitis, Meningococcal (3) · COVID-19 (2) · Coronavirus Infections (2) · Dysentery, Bacillary (2) · Hemorrhagic Fever, Ebola (2) · Central Nervous System Diseases (1) · Hemorrhagic Fevers, Viral (1) · Nervous System Diseases (1) · Salmonella Infections (1) · Sepsis (1)
GlaxoSmithKline (7) · University of Oxford (3) · Janssen Vaccines & Prevention B.V. (2) · LimmaTech Biologics AG (2) · Novartis Vaccines (1)
Australia (2) · Brazil (2) · Czechia (2) · Estonia (2) · Finland (2) · Kenya (2) · Mexico (2) · Sierra Leone (2) · Turkey (Türkiye) (2) · United Kingdom (2) · United States (2) · Argentina (1) · Canada (1) · France (1) · Germany (1)
Andrew Pollard, Prof (2) · Andrew Pollard, FRCPCH, PhD (1) · Josphat Kosgei, MD (1) · Mainga Hamaluba, MD (1) · Richard Omore, PhD (1)
PMID 29895178, PMID 30061029, PMID 32702298, PMID 33306989, PMID 33335322, PMID 33617777, PMID 34480858, PMID 34529962, PMID 34529963, PMID 34787449, PMID 35257644, PMID 36369456, PMID 37138460, PMID 37631885, PMID 37858585, PMID 38603720, PMID 39647494, PMID 39675209, PMID 40686533
2017 (3), 2019 (2), 2014 (1), 2016 (1)